What is Bionomics?
Bionomics is a global, clinical-stage biopharmaceutical company dedicated to developing a pipeline of novel drug candidates. The company's primary focus is on transforming the lives of patients suffering from serious Central Nervous System (CNS) disorders. Its strategic approach involves advancing therapeutic solutions through rigorous clinical development, aiming to address unmet medical needs in a challenging therapeutic area.
How much funding has Bionomics raised?
Bionomics has raised a total of $88.1M across 3 funding rounds:
Private Equity
$638K
Stock Offering
$17.5M
Other Financing Round
$70M
Private Equity (2021): $638K with participation from NovaMind
Stock Issuance/Offering (2021): $17.5M, investors not publicly disclosed
Other Financing Round (2024): $70M, investors not publicly disclosed
What's next for Bionomics?
The recent major enterprise-level funding indicates Bionomics is poised for significant scaling and advancement of its clinical pipeline. This capital infusion is expected to accelerate the development of its drug candidates, potentially moving them through later-stage clinical trials and towards regulatory submission. The company's trajectory suggests a strong emphasis on strategic partnerships and continued research and development to solidify its position in the competitive CNS disorder market.
See full Bionomics company page
